As these results strongly suggested an involvement of NK cells and CD16 in depleting B cells from GPA patients, we hypothesized that obinutuzumab which is characterized by an increased affinity to CD16 would lead to stronger NK cell activation. The gene discussed is FCGR3A; the disease is granulomatosis with polyangiitis.